Eckert & Ziegler Strahlen- und Medizintechnik AG Logo

Eckert & Ziegler Strahlen- und Medizintechnik AG

A global provider of isotope technology for medical, scientific, and industrial use.

EUZ | F

Overview

Corporate Details

ISIN(s):
DE0005659700
LEI:
391200EUDABLUKXCKG48
Country:
Germany
Address:
Robert-Rössle-Str. 10, 13125 Berlin

Description

Eckert & Ziegler Strahlen- und Medizintechnik AG is a global provider of isotope technology for medical, scientific, and industrial use. The company's core business focuses on cancer therapy, industrial radiometry, and nuclear-medical imaging. It specializes in developing and manufacturing radioactive components and related equipment. Key offerings for the medical sector include products and services for nuclear medicine and radiation therapy, such as radiopharmaceuticals, radiosynthesis and quality control (QC) solutions, and sealed radiation sources. The company also provides essential infrastructure like hot cells and radiation protection solutions, supporting the radiopharmaceutical industry from early development through to commercial production.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-12 10:30
Eckert & Ziegler Proposes Dividend of 0.50 for FY 2024
English 5.7 KB
2025-04-11 11:38
Eckert & Ziegler SE: Dr. Harald Hasselmann, Allocation of 18,048 shares as part…
English 6.1 KB
2025-04-10 15:00
Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschwe…
English 7.1 KB
2025-03-27 07:45
Eckert & Ziegler: Record year 2024 with new all-time highs
English 7.5 KB
2025-03-25 09:30
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensi…
English 10.4 KB
2025-03-21 19:45 English 4.4 KB
2025-03-21 14:00
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lut…
English 8.6 KB
2025-03-20 14:00
Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lut…
English 8.6 KB
2025-02-28 15:00
Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Rad…
English 8.1 KB
2025-02-27 15:00
Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Rad…
English 8.1 KB
2025-02-26 09:59
Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
English 6.4 KB
2025-02-25 09:59
Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
English 6.4 KB
2025-02-14 09:21
Eckert & Ziegler Affected by Cyber Attack
English 5.6 KB
2025-02-13 09:21
Eckert & Ziegler Affected by Cyber Attack
English 5.6 KB
2025-02-03 13:23
Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Ch…
English 6.6 KB

Automate Your Workflow. Get a real-time feed of all Eckert & Ziegler Strahlen- und Medizintechnik AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eckert & Ziegler Strahlen- und Medizintechnik AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eckert & Ziegler Strahlen- und Medizintechnik AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-08-30 Eckert, Dr. Andreas Supervisory board Sell None 1,526,400.00 EUR
2023-08-30 Eckert Wagniskapital und Frühphasenfinanzierung GmbH Close relation Buy None 1,526,400.00 EUR
2023-08-11 Perschmann, Frank Supervisory board Buy None 16,600.00 EUR
2023-01-13 NEON Equity AG Close relation Buy None 2,115.00 EUR
2023-01-12 Blunck, Dr. Thomas Board Sell None 57,402.00 EUR
2023-01-12 Blunck, Dr. Thomas Board Sell None 32,160.00 EUR
2023-01-11 Bouterfa, Dr. Hakim Board Buy None 124,800.00 EUR
2022-12-21 Eckert Wagniskapital und Frühphasenfinanzierung GmbH Close relation Buy None 1,432,800.00 EUR
2022-12-06 Maennig, Prof. Dr. Wolfgang Supervisory board Buy None 72,745.31 EUR
2022-12-05 Carpio GmbH Close relation Buy None 73,826.53 EUR

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.